Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis

Mori, Shunsuke; Koga, Yukinori; Sugimoto, Mineharu

doi:10.1016/j.rmed.2012.07.006

Cited by 186 publications

(152 citation statements)

References 48 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…In contrast, anti-centromere antibodies are associated with limited cutaneous disease and increased risk of PH [19,57]. In RA, rheumatoid factor and anti-citrullinated protein antibodies have been associated with ILD [58,59,60]. In PM/DM, anti-Jo-1 and anti-SSA/Ro antibodies have also been found to be linked with severe and extensive ILD [61].…”

Section: Pulmonary ‘Disease Activity' In Monitoringmentioning

confidence: 99%

Monitoring of Lung Involvement in Rheumatologic Disease

Paschalaki

Jacob²,

Wells

2016

Respiration

View full text Add to dashboard Cite

The monitoring of lung involvement in patients with connective tissue diseases is central to optimal long-term management and is directed towards: (a) the detection of supervening lung involvement not present at presentation and (b) the identification of disease progression in established lung disease. For both goals, accurate surveillance requires multi-disciplinary evaluation with the integration of symptomatic change, serial pulmonary function trends and imaging data. Evaluated in isolation, each of these monitoring domains has significant limitations. Symptomatic change may be confounded by a wide variety of systemic factors. Pulmonary function tests provide the most reliable data, but are limited by measurement variability, the heterogeneity of functional patterns and the confounding effects of non-pulmonary factors. Chest radiography is insensitive to change but may provide rapid confirmation of major disease progression or alert the clinician to respiratory co-morbidities. Although high-resolution computed tomography has a central role in assessing disease severity, it should be used very selectively as a monitoring tool due to the associated radiation burden. Ancillary tests include echocardiography and exercise testing to proactively identify cases of pulmonary hypertension and worsening of oxygenation. In summary, a multi-disciplinary approach is essential for the identification of disease progression and prompt treatment of comorbidities that severely impact on the morbidity and mortality of disease.

show abstract

Section: Pulmonary ‘Disease Activity' In Monitoringmentioning

confidence: 99%

Monitoring of Lung Involvement in Rheumatologic Disease

Paschalaki

Jacob²,

Wells

2016

Respiration

View full text Add to dashboard Cite

show abstract

“…Numerous studies have found that BR precedes RA often by 20-30 years 1,8,13,14 , supporting the hypothesis that BR may be involved in the pathogenesis of RA 1,8,13,14 8,13,18,19 . Initially no link between anti-CCP and lung disease was found 20 , but two studies have reported an association between anti-CCP and airways disease 21 and interstitial lung disease 22 in patients with established RA.…”

Section: Introductionmentioning

confidence: 99%

Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co‐existent bronchiectasis

et al. 2015

View full text Add to dashboard Cite

AimPatients with rheumatoid arthritis (RA) and co‐existent bronchiectasis (BRRA) have a five‐fold increased mortality compared to rheumatoid arthritis alone. Yet previous studies have found no difference in clinical and serological markers of RA disease severity between BRRA patients and RA alone. However, RA disease activity measures such as Disease Activity Score of 28 joints – C‐reactive protein (DAS28‐CRP) and anti‐cyclic citrullinated peptide antibodies (anti‐CCP) have not been studied, so we assessed these parameters in patients with BRRA and RA alone.MethodsBRRA patients (n = 53) had high‐resolution computed tomography proven bronchiectasis without any interstitial lung disease and ≥ 2 respiratory infections/year. RA alone patients (n = 50) had no clinical or radiological evidence of lung disease. DAS28‐CRP, rheumatoid factor (immunoglobulin M) and anti‐CCP were measured in all patients, together with detailed clinical and radiology records.ResultsIn BRRA, bronchiectasis predated RA in 58% of patients. BRRA patients had higher DAS28 scores (3.51 vs. 2.59), higher levels of anti‐CCP (89% vs. 46%) and rheumatoid factor (79% vs. 52%) (P = 0.003) compared to RA alone. Where hand and foot radiology findings were recorded, 29/37 BRRA (78%) and 13/30 (43%) RA alone had evidence of erosive change (P = 0.003). There were no significant differences between groups in smoking history or disease‐modifying anti‐rheumatic drug/biologic therapy.ConclusionsIncreased levels of RA disease activity, severity and RA autoantibodies are demonstrated in patients with RA and co‐existent bronchiectasis compared to patients with RA alone, despite lower tobacco exposure. This study demonstrates that BRRA is a more severe systemic disease than RA alone.

show abstract

“…Yap›lan bir çal›flmada RA'l› hastalarda 65 yafl›n üzerinde olman›n ‹AH geliflme riskini 4 kat art›rd›¤› gösterilmifltir. [34] Sigara, RA geliflimi için bir risk faktörüdür. [35] ‹çilen paket/y›l miktar› artt›kça RA geliflme riski de o oranda art›fl göste-rir.…”

Section: Risk Faktörleriunclassified

Rheumatoid arthritis-associated interstitial lung disease

Beş¹

2015

RAED Derg

View full text Add to dashboard Cite

Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis

Abstract: The differential associations of ILD and AD with various clinical and genetic factors suggest that ILD and AD have distinct etiologies in RA.

Cited by 186 publications

References 48 publications

Monitoring of Lung Involvement in Rheumatologic Disease

Monitoring of Lung Involvement in Rheumatologic Disease

Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co‐existent bronchiectasis

Rheumatoid arthritis-associated interstitial lung disease

Contact Info

Product

Resources

About